<prompt> True regarding DenosumabStrong antiresorptive actionBinds RANKL prevents its binding to receptor RANKAtypical femoral fracture as one of the adverse effectsAll of the above  <response>: Denosumab, an antibody that blocks the RANK ligand RANKL and dramatically reduces osteoclast number and function, is approved for therapy of osteoporosis. It also appears to be an effective treatment to reverse hypercalcemia of malignancy. Jaw necrosis, atypical femoral fracture, skin infections , occasional severe hypocalcemia are the side effects. Ref Harrison 20th edi page no 2956 